GNRH1 and adenomyosis: GnRH-a is markedly efficient in controlling dysmenorrhea and menorrhagia and reducing uterine size for adenomyosis.28,29 However, the acceptability of and adherence to GnRH-a treatment are much lower than expected owing to its high cost and high rates of adverse effects and bone resorption.30 In this study, mifepristone was as effective, if not more effective than GnRH-a, in controlling dysmenorrhea.31 Furthermore, mifepristone has a relatively low price for long-term treatment.